Hereditary Hemochromatosis: HFE, C282Y, and Diagnosis
Hemochromatosis is the most common inherited iron-overload disorder in populations of Northern European ancestry. The classic form results from biallelic variants in HFE, which disrupt hepcidin signaling and allow unchecked intestinal iron absorption. Excess iron then deposits in the liver, heart, pancreas, joints, and endocrine glands.
Frequently asked questions
Is everyone with two HFE mutations affected?
No. Penetrance is incomplete and influenced by sex, age, alcohol use, and other factors. Many p.C282Y homozygotes never develop overt clinical disease, though biochemical iron overload is common and risk rises with age.
Do compound heterozygotes develop iron overload?
Compound heterozygotes (p.C282Y/p.H63D) generally have lower iron indices than p.C282Y homozygotes and a much lower risk of clinical disease. Significant overload in this group usually requires an additional cofactor.
The molecular mechanism: HFE and iron accumulation
The HFE protein helps regulate iron absorption. When it loses function, the signal that normally limits iron uptake in the gut weakens, so iron absorbed from food keeps building up in the body. The excess deposits in the liver, heart, pancreas, and other organs, and over time can lead to fibrosis, cirrhosis, cardiomyopathy, and diabetes.
Among HFE variants, p.C282Y is the most clinically significant. The p.C282Y homozygous genotype accounts for more than 90% of typical hereditary hemochromatosis cases, with symptoms usually emerging after age 40.
Penetrance is incomplete—and sex matters
Genotype does not equal phenotype in hemochromatosis. Large prospective data have reshaped how clinicians should think about risk. In a UK Biobank cohort of 451,270 participants of European genetic ancestry followed for a mean of 13.3 years, investigators tracked clinical outcomes by HFE genotype.
The male findings were striking. Male p.C282Y homozygotes had higher mortality (33.1% vs 25.4%; HR 1.29, 95% CI 1.12–1.48), more joint replacements (27.9% vs 17.1%), and more liver disease (20.3% vs 8.3%), along with excess delirium, dementia, and Parkinson’s disease.
Women were affected too, though less dramatically. Female homozygotes showed increased joint replacement surgery (23.2% vs 21.1%) and raised brain outcomes (8.6% vs 7.4%; HR 1.30), including delirium (5.9% vs 3.9%). Menstruation and pregnancy likely offer partial protection through physiologic iron loss, delaying presentation.
The underdiagnosis problem
Among women with p.C282Y homozygosity, only 3.4% had a hemochromatosis diagnosis at baseline, yet cumulative incidence reached 40.5% by age 80, with excess incident liver disease (8.9% vs 6.8%; HR 1.62). For the individual clinician, the message is simpler: keep hemochromatosis on the differential for unexplained fatigue, arthralgia, transaminitis, or new diabetes.
Interpreting iron studies before genetic testing
Fasting transferrin saturation is the most sensitive first-line screening marker, read together with ferritin. When both stay persistently elevated, the next step is genetic testing.
One caveat: in a compound heterozygote (C282Y/H63D) with markedly high ferritin, the overload usually isn’t driven by HFE alone—another factor such as alcohol, fatty liver, or inflammation is typically also at play.
When to pursue genetic testing
Consider HFE genotyping when transferrin saturation and ferritin are persistently elevated, when a first-degree relative carries a known genotype, or when unexplained liver, joint, cardiac, or endocrine findings suggest iron overload. A confirmed genotype supports cascade testing of relatives, allowing at-risk individuals to be identified before organ damage occurs.
Rarer, non-HFE forms—caused by variants in HJV, HAMP, TFR2, or SLC40A1—should be considered when the phenotype is convincing but HFE testing is negative, particularly in younger patients or those of non-European ancestry. Broader panel or exome testing can clarify these atypical presentations.
Hemochromatosis rewards early recognition: iron depletion therapy is effective and inexpensive when started before cirrhosis or cardiomyopathy develop.
* This article is educational and does not replace individualized medical advice. Diagnostic and management decisions should be made with a qualified clinician.
Want to learn more about
3billion's genetic testing?
We'll reply within 1 business day.
References
- Grosse SD et al, Clinical penetrance in hereditary hemochromatosis: estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes, 2017, 10.1038/gim.2017.121, https://doi.org/10.1038/gim.2017.121
- Kowdley KV et al, ACG Clinical Guideline: Hereditary Hemochromatosis, 2019, 10.14309/ajg.0000000000000315, https://doi.org/10.14309/ajg.0000000000000315
- Girelli D et al, Diagnosis and management of hereditary hemochromatosis: lifestyle modification, phlebotomy, and blood donation, 2024, 10.1182/hematology.2024000568, https://doi.org/10.1182/hematology.2024000568
- Lucas MR et al, HFE genotypes, haemochromatosis diagnosis and clinical outcomes at age 80 years: a prospective cohort study in the UK Biobank, 2024, 10.1136/bmjopen-2023-081926, https://doi.org/10.1136/bmjopen-2023-081926
Soo-jung Baek
Marketing Manager
I strive to empower the rare disease community by sharing meaningful insights backed by our company’s expertise.
